Published • loading... • Updated
Ionis Pharmaceuticals, Inc. (IONS) Stock Analysis: Assessing Growth Potential with a 57.94% Upside
Summary by DirectorsTalk Interviews
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Ionis Pharmaceuticals, Inc. (IONS) Stock Analysis: Assessing Growth Potential with a 57.94% Upside
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) stands as a significant player in the biotechnology sector, a space known for its innovative strides in healthcare solutions. With a market capitalization of $9.4 billion, Ionis is a commercial-stage biotechnology company that has carved a niche in RNA-targeted medicines, offering a range of treatments from acute pancreatitis to spinal muscular atrophy (SMA). Currently trading at $56.56, Ionis has exper…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
